Different tests can tell different truths about the same person. Clinical reasoning connects them.
A laboratory report may look reassuring while another result raises questions. Rather than asking which test is “right,” it is often more useful to ask whether the tests were intended to answer the same question at all.
This article offers a framework for discussing cardiovascular risk with your own health care professional. It is not a checklist of tests everyone needs or an online treatment plan.
Separate the measurement from the decision
LDL-C measures cholesterol carried in LDL particles. Non-HDL cholesterol, calculated by subtracting HDL-C from total cholesterol, captures cholesterol carried across atherogenic lipoproteins. ApoB offers a measure of atherogenic particle concentration. These quantities are related but may be discordant in an individual. [10]
Lp(a) adds a largely inherited component of risk. CAC adds evidence about calcified coronary plaque. Neither can be inferred reliably from a routine LDL-C result, and neither replaces the rest of the assessment. [6,11]
One way to organize the conversation is to keep three questions separate: what is circulating now, what evidence of disease is detectable, and what future decision is being considered?
Why a “normal” number is not a universal target
A reference range on a laboratory report is not the same as a personalized prevention goal. Existing cardiovascular disease, diabetes, kidney disease, family history, and other factors can change the importance of the same lipid result. Prevention requires a risk-based, patient-centered assessment rather than a single universal cutoff. [16]
It also matters whether the result was measured before or during treatment. When reviewing a report, bring the medication history rather than letting an isolated value speak for itself.
An appointment becomes more productive when both people understand the question: are we estimating untreated risk, assessing a response, or deciding whether additional information would change care?
A brief glossary, with a practical limit
Think of LDL-C as cholesterol content, ApoB as particle concentration, and non-HDL-C as a broader cholesterol measure. This is a useful orientation, not a claim that one test makes the others obsolete. ApoB can be particularly helpful when the number of particles and their cholesterol content do not tell the same story. [10]
Lp(a) deserves a separate discussion. Its cardiovascular association is continuous, and results should be interpreted in their reported units. A fixed conversion between mg/dL and nmol/L is not reliable across individuals. A clinician should not reconstruct an Lp(a) result from another person's conversion table. [11]
Three decision conversations
These are fictional educational situations, not patient histories or prescribing examples.
Conversation A: “My LDL-C improved. Why did the scan still find calcium?”
Improving a circulating marker does not mean that all previously developed plaque becomes undetectable. CAC is not a pass–fail measure of a medication's benefit. Serial CT research has linked statin therapy to denser calcification and less lipid-rich plaque, illustrating why a score alone cannot describe every relevant plaque change. [7]
The useful question is what the complete result adds to future prevention, not whether one number invalidates the treatment history.
Conversation B: “Does CAC zero cancel an elevated Lp(a)?”
No. Observational evidence from MESA and the Dallas Heart Study shows that these markers provide different information. CAC zero may lower concern about near-term events in an appropriate context without erasing an inherited risk factor or establishing lifetime safety. [6]
The next conversation should focus on what is modifiable, what needs follow-up, and what would actually change a decision. Repeated imaging is not an automatic response to uncertainty.
Conversation C: “Should I get every available test before deciding?”
Not necessarily. Ask your clinician to identify the unresolved decision first. Perhaps the next useful step is confirming blood pressure, reviewing prior results, clarifying family history, or checking whether the current plan is practical. A more elaborate panel is not automatically a more useful assessment.
Where imaging is being considered, it should have a defined role. Selective CAC assessment is different from treating a scan as an entry requirement for prevention. [14,16]
Use the right risk framework for the right question
For relevant primary-prevention discussions in the United States, the 2026 guideline uses PREVENT-ASCVD rather than simply carrying forward the older Pooled Cohort Equations. A result from one framework should not be interpreted with thresholds copied from another. [1]
A numerical estimate also does not remove clinical judgment. The estimate, additional risk information, possible benefit, adverse effects, treatment burden, and patient preferences need to be considered together.
This matters across countries as well. An English-language article can explain the science without claiming that a Brazilian guideline and a U.S. guideline are interchangeable.
Prediction is not the same as proof of benefit
CAC has substantial prognostic evidence. A higher score is associated with more cardiovascular events, but that fact does not prove that every person benefits from having the test. [4]
The CAUGHT-CAD trial adds evidence about a structured prevention strategy informed by CAC, with slower plaque progression in selected participants. It does not make every unresolved prevention question an indication for CT, and its imaging endpoint should not be presented as demonstrated mortality reduction. [8]
A good clinical explanation preserves both sides: why a result may be useful and what it still cannot establish.
Finish with a plan, not just a label
A useful visit should leave you able to explain what was learned, which uncertainty remains, what you and your clinician decided, and what will trigger reassessment. The plan should be feasible enough to follow and flexible enough to review when circumstances change.
New symptoms belong in a different conversation. A previous CAC zero should not delay urgent assessment of possible heart attack symptoms; call 911 in the United States when these are suspected. [13]
Continue with LDL-C, non-HDL-C, and ApoB and lipoprotein(a). For complementary education, register your interest in the MERHI ONE Global newsletter, an independent educational project. Email publication has not started.
The aim is not to collect the most results. It is to understand which results help you and your clinician make a better-informed decision.
Educational content only. Dr. Elias Tamer Merhi Júnior is a physician licensed in Brazil, CRM-GO 14.866 and CRM-DF 17.740. This website does not offer medical services in the United States and does not replace care from your own health care professional.
References
[1] Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. Published March 13, 2026. DOI: 10.1161/CIR.0000000000001423. Source: https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia/top-things-to-know
[4] Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J. 2018;39(25):2401–2408. DOI: 10.1093/eurheartj/ehy217. Source: https://pubmed.ncbi.nlm.nih.gov/29688297/
[6] Mehta A, et al. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. J Am Coll Cardiol. 2022. DOI: 10.1016/j.jacc.2021.11.058. Source: https://pubmed.ncbi.nlm.nih.gov/35210030/
[7] van Rosendael AR, van den Hoogen IJ, Gianni U, et al. Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition. JAMA Cardiol. 2021;6(11):1257–1266. DOI: 10.1001/jamacardio.2021.3055. Source: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783117
[8] Nerlekar N, Vasanthakumar S, Whitmore K, et al. Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2025;333(16):1403–1412. DOI: 10.1001/jama.2025.0584. Source: https://jamanetwork.com/journals/jama/fullarticle/2831115
[10] Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647–e663. DOI: 10.1016/j.jacl.2024.08.013. Source: https://pubmed.ncbi.nlm.nih.gov/39256087/
[11] Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946. DOI: 10.1093/eurheartj/ehac361. Source: https://doi.org/10.1093/eurheartj/ehac361
[13] American Heart Association Warning Signs of a Heart Attack. Official public information. Accessed September 19, 2026. Source: https://www.heart.org/en/health-topics/heart-attack/warning-signs-of-a-heart-attack
[14] Blaha MJ, Mortensen MB, Kianoush S, Tota-Maharaj R, Cainzos-Achirica M Coronary Artery Calcium Scoring: Is It Time for a Change in Methodology?. JACC Cardiovasc Imaging. 2017;10(8):923–937. DOI: 10.1016/j.jcmg.2017.05.007. Source: https://www.jacc.org/doi/10.1016/j.jcmg.2017.05.007
[16] Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019;74(10):e177–e232. DOI: 10.1016/j.jacc.2019.03.010. Source: https://www.jacc.org/doi/10.1016/j.jacc.2019.03.010